Panelists discuss how the evolution of anal cancer treatment began with the 1974 Nigro regimen combining 5-fluorouracil and ...

Panelists discuss how successful treatment of locally advanced anal cancer requires a multidisciplinary approach involving ...

FDA accelerates approval of sunvozertinib for advanced NSCLC with EGFR mutations, offering new hope for patients after ...

The SonoClear System revolutionizes neurosurgery with FDA breakthrough designation, enhancing ultrasound imaging for safer ...

Andrew Evens, DO, MBA, MSc, discusses the HOLISTIC consortium, which aims to gather and harmonize global Hodgkin lymphoma ...

The FDA designates the TOBY Test as a breakthrough device, revolutionizing bladder cancer detection with a non-invasive, ...

Panelists discuss the rapidly evolving endocrine treatment landscape in oncology, emphasizing the shift toward personalized ...

During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone ...

Orca-T shows significant promise in reducing chronic graft-vs-host disease and improving survival rates in allogeneic ...

During a live event, Mojtaba Akhtari, MD, discussed trials studying patients with high-risk polycythemia vera.

The FDA has granted accelerated approval to linvoseltamab-gcpt (Lynozyfic) for the treatment of adult patients with ...

Panelists discuss recent phase 3 trials of novel endocrine agents in advanced breast cancer, highlighting benefits—especially ...